View Item 

Show simple item record

Emerging biomarkers in psoriatic arthritis
dc.contributor.authorPaek, So Yeon
dc.contributor.authorHan, Ling
dc.contributor.authorWeiland, Matthew
dc.contributor.authorLu, Chuan‐jian
dc.contributor.authorMcKinnon, Kathleen
dc.contributor.authorZhou, Li
dc.contributor.authorLim, Henry W.
dc.contributor.authorElder, James T.
dc.contributor.authorMi, Qing‐sheng
dc.date.accessioned2017-04-13T20:35:16Z
dc.date.available2017-04-13T20:35:16Z
dc.date.issued2015-12
dc.identifier.citationPaek, So Yeon; Han, Ling; Weiland, Matthew; Lu, Chuan‐jian ; McKinnon, Kathleen; Zhou, Li; Lim, Henry W.; Elder, James T.; Mi, Qing‐sheng (2015). "Emerging biomarkers in psoriatic arthritis." IUBMB Life 67(12): 923-927.
dc.identifier.issn1521-6543
dc.identifier.issn1521-6551
dc.identifier.urihttps://hdl.handle.net/2027.42/136299
dc.description.abstractPsoriasis is an immuneâ mediated skin disease which affects 2â 4% of the worldwide population. Approximately 20â 30% of patients with psoriasis develop psoriatic arthritis (PsA), a frequently destructive and disabling condition. As skin manifestations precede joint symptoms in nearly all patients with PsA, identification of biomarkers for early prediction of joint damage is an important clinical need. Because not all patients with PsA respond to treatment in the same fashion, identification of biomarkers capable of predicting therapeutic response is also imperative. Here, we review existing literature and discuss current investigations to identify potential biomarkers for PsA disease activity, with particular emphasis on microRNAs as novel markers of interest. Serum (soluble) biomarkers, peripheral osteoclast precursor as cellular biomarkers, and genetic loci associated with skin and joint disease are also reviewed. © 2015 IUBMB Life, 67(12):923â 927, 2015
dc.publisherWiley Periodicals, Inc.
dc.subject.othermicroRNAs
dc.subject.otherpsoriatic arthritis
dc.subject.otherbiomarkers
dc.titleEmerging biomarkers in psoriatic arthritis
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelEcology and Evolutionary Biology
dc.subject.hlbtoplevelScience
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/136299/1/iub1453.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/136299/2/iub1453_am.pdf
dc.identifier.doi10.1002/iub.1453
dc.identifier.sourceIUBMB Life
dc.identifier.citedreferenceReich, K., Hüffmeier, U., König, I. R., Lascorz, J., Lohmann, J., et al. ( 2007 ) TNF polymorphisms in psoriasis: association of psoriatic arthritis with the promoter polymorphism TNF*â 857 independent of the PSORS1 risk allele. Arthritis Rheum. 56, 2056 â 2064.
dc.identifier.citedreferenceSato, K., Suematsu, A., Okamoto, K., Yamaguchi, A., Morishita, Y., et al. ( 2006 ) Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J. Exp. Med. 203, 2673 â 2682.
dc.identifier.citedreferenceChiu, Y. H., Mensah, K. A., Schwarz, E. M., Ju, Y., Takahata, M., et al. ( 2012 ) Regulation of human osteoclast development by dendritic cellâ specific transmembrane protein (DCâ STAMP). J. Bone Miner. Res. 27, 79 â 92.
dc.identifier.citedreferenceMizoguchi, T., Muto, A., Udagawa, N., Arai, A., Yamashita, T., et al. ( 2009 ) Identification of cell cycleâ arrested quiescent osteoclast precursors in vivo. J. Cell Biol. 184, 541 â 554.
dc.identifier.citedreferenceChiu, Y. G., Shao, T., Feng, C., Mensah, K. A., Thullen, M., et al. ( 2010 ) CD16 (FcRγIII) as a potential marker of osteoclast precursors in psoriatic arthritis. Arthritis Res. Ther. 12, R14.
dc.identifier.citedreferenceElder, J. T., Bruce, A. T., Gudjonsson, J. E., Johnston, A., Stuart, P. E., et al. ( 2010 ) Molecular dissection of psoriasis: integrating genetics and biology. J. Invest. Dermatol. 130, 1213 â 1226.
dc.identifier.citedreferenceOkada, Y., Han, B., Tsoi, L. C., Stuart, P. E., Ellinghaus, E., et al. ( 2014 ) Fine mapping major histocompatibility complex associations in psoriasis and its clinical subtypes. Am. J. Hum. Genet. 95, 162 â 172.
dc.identifier.citedreferenceNair, R. P., Stuart, P. E., Nistor, I., Hiremagalore, R., Chia, N. V., et al. ( 2006 ) Sequence and haplotype analysis supports HLAâ C as the psoriasis susceptibility 1 gene. Am. J. Hum. Genet. 78, 827 â 851.
dc.identifier.citedreferenceStrange, A., Capon, F., Spencer, C. C., Knight, J., Weale, M. E., et al.; the Genetic Analysis of Psoriasis Consortium and the Wellcome Trust Case Control Consortium. ( 2010 ) A genomeâ wide association study identifies new psoriasis susceptibility loci and an interaction between HLAâ C and ERAP1. Nat. Genet. 42, 985 â 990.
dc.identifier.citedreferenceStuart, P. E., Nair, R. P., Ellinghaus, E., Ding, J., Tejasvi, T., et al. ( 2010 ) Genomeâ wide association analysis identifies three psoriasis susceptibility loci. Nat. Genet. 42, 1000 â 1004.
dc.identifier.citedreferenceEder, L., Chandran, V., Pellett, F., Pollock, R., Shanmugarajah, S., et al. ( 2011 ) IL13 gene polymorphism is a marker for psoriatic arthritis among psoriasis patients. Ann. Rheum. Dis. 70, 1594 â 1598.
dc.identifier.citedreferencePrietoâ Pérez, R., Cabaleiro, T., Daudén, E., and Abadâ Santos, F. ( 2013 ) Gene polymorphisms that can predict response to antiâ TNF therapy in patients with psoriasis and related autoimmune diseases. Pharmacogenomics J. 13, 297 â 305.
dc.identifier.citedreferenceTejasvi, T., Stuart, P. E., Chandran, V., Voorhees, J. J., Gladman, D. D., et al. ( 2012 ) TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis. J. Invest. Dermatol. 132, 593 â 600.
dc.identifier.citedreferenceBalding, J., Kane, D., Livingstone, W., Mynettâ Johnson, L., Bresnihan, B., et al. ( 2003 ) Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity. Arthritis Rheum. 48, 1408 â 1413.
dc.identifier.citedreferenceFiler, C., Ho, P., Smith, R. L., Griffiths, C., Young, H. S., et al. ( 2008 ) Investigation of association of the IL12B and IL23R genes with psoriatic arthritis. Arthritis Rheum. 58, 3705 â 3709.
dc.identifier.citedreferenceRahman, P., and Elder, J. T. ( 2012 ) Genetics of psoriasis and psoriatic arthritis: a report from the GRAPPA 2010 annual meeting. J. Rheumatol. 39, 431 â 433.
dc.identifier.citedreferenceChen, H., Poon, A., Yeung, C., Helms, C., Pons, J., et al. ( 2011 ) A genetic risk score combining ten psoriasis risk loci improves disease prediction. PLoS One 6, e19454.
dc.identifier.citedreferenceCallis Duffin, K., Armstrong, A. W., and Mease, P. J. ( 2012 ) Psoriasis and psoriatic arthritis video project: an update from the GRAPPA 2011 annual meeting. J. Rheumatol. 39, 2198 â 2200.
dc.identifier.citedreferenceWeiland, M., Gao, X. H., Zhou, L., and Mi, Q. S. ( 2012 ) Small RNAs have a large impact: circulating microRNAs as biomarkers for human diseases. RNA Biol. 9, 850 â 859.
dc.identifier.citedreferenceTang, H., Jin, X., Li, Y., Jiang, H., Tang, X., et al. ( 2014 ) A largeâ scale screen for coding variants predisposing to psoriasis. Nat. Genet. 46, 45 â 50.
dc.identifier.citedreferencePivarcsi, A., Meisgen, F., Xu, N., StÃ¥hle, M., and Sonkoly, E. ( 2013 ) Changes in the level of serum microRNAs in patients with psoriasis after antitumour necrosis factorâ α therapy. Br. J. Dermatol. 169, 563 â 570.
dc.identifier.citedreferenceGudjonsson, J. E., Johnston, A., and Ellis, C. N. ( 2012 ) Novel systemic drugs under investigation for the treatment of psoriasis. J. Am. Acad. Dermatol. 67, 139 â 147.
dc.identifier.citedreferenceFitzGerald, O., and Mease, P. J. ( 2013 ) Biomarkers: project update from the GRAPPA 2012 annual meeting. J. Rheumatol. 40, 1453 â 1454.
dc.identifier.citedreferenceRitchlin, C. T. ( 2012 ) Strategies for biomarker development in psoriatic disease: a report from the GRAPPA 2010 annual meeting. J. Rheumatol. 39, 423 â 426.
dc.identifier.citedreferenceLundberg, K. C., Fritz, Y., Johnston, A., Foster, A. M., Baliwag, J., et al. ( 2015 ) Proteomics of skin proteins in psoriasis: from discovery and verification in a mouse model to confirmation in humans. Mol. Cell. Proteomics 14, 109 â 119.
dc.identifier.citedreferenceMiller, I. M., Ellervik, C., Yazdanyar, S., and Jemec, G. B. ( 2013 ) Metaâ analysis of psoriasis, cardiovascular disease, and associated risk factors. J. Am. Acad. Dermatol. 69, 1014 â 1024.
dc.identifier.citedreferencePouplard, C., Brenaut, E., Horreau, C., Barnetche, T., Misery, L., et al. ( 2013 ) Risk of cancer in psoriasis: a systematic review and metaâ analysis of epidemiological studies. J. Eur. Acad. Dermatol. Venereol. 27, 36 â 46.
dc.identifier.citedreferenceDi Cesare, A., Di Meglio, P., and Nestle, F. O. ( 2009 ) The ILâ 23/Th17 axis in the immunopathogenesis of psoriasis. J. Invest. Dermatol. 129, 1339 â 1350.
dc.identifier.citedreferenceZachariae, H. ( 2003 ) Prevalence of joint disease in patients with psoriasis: implications for therapy. Am. J. Clin. Dermatol. 4, 441 â 447.
dc.identifier.citedreferenceGladman, D. D., Antoni, C., Mease, P., Clegg, D. O., and Nash, P. ( 2005 ) Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann. Rheum. Dis. 64, ii14 â ii17.
dc.identifier.citedreferenceHaroon, M., Kirby, B., and FitzGerald, O. ( 2013 ) High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann. Rheum. Dis. 72, 736 â 740.
dc.identifier.citedreferenceVillanova, F., Di Meglio, P., and Nestle, F. O. ( 2013 ) Biomarkers in psoriasis and psoriatic arthritis. Ann. Rheum. Dis. 72 ( Suppl 2), ii104 â ii110.
dc.identifier.citedreferenceRyan, C., Korman, N. J., Gelfand, J. M., Lim, H. W., Elmets, C. A., et al. ( 2014 ) Research gaps in psoriasis: opportunities for future studies. J. Am. Acad. Dermatol. 70, 146 â 167.
dc.identifier.citedreferenceArican, O., Aral, M., Sasmaz, S., and Ciragil, P. ( 2005 ) Serum levels of TNFâ α, IFNâ γ, ILâ 6, ILâ 8, ILâ 12, ILâ 17, and ILâ 18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm. 2005, 273 â 279.
dc.identifier.citedreferenceKagami, S., Rizzo, H. L., Lee, J. J., Koguchi, Y., and Blauvelt, A. ( 2010 ) Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J. Invest. Dermatol. 130, 1373 â 1383.
dc.identifier.citedreferenceTonel, G., Conrad, C., Laggner, U., Di Meglio, P., Grys, K., et al. ( 2010 ) Cutting edge: a critical functional role for ILâ 23 in psoriasis. J. Immunol. 185, 5688 â 5691.
dc.identifier.citedreferenceEder, L., Jayakar, J., Pollock, R., Pellett, F., Thavaneswaran, A., et al. ( 2013 ) Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity. Ann. Rheum. Dis. 72, 1956 â 1961.
dc.identifier.citedreferenceLiu, Y., Helms, C., Liao, W., Zaba, L. C., Duan, S., et al. ( 2008 ) A genomeâ wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet. 4, e1000041.
dc.identifier.citedreferenceShibata, S., Tada, Y., Hau, C., Tatsuta, A., Yamamoto, M., et al. ( 2011 ) Adiponectin as an antiâ inflammatory factor in the pathogenesis of psoriasis: induction of elevated serum adiponectin levels following therapy. Br. J. Dermatol. 164, 667 â 670.
dc.identifier.citedreferenceJohnston, A., Arnadottir, S., Gudjonsson, J. E., Aphale, A., Sigmarsdottir, A. A., et al. ( 2008 ) Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation. Br. J. Dermatol. 159, 342 â 350.
dc.identifier.citedreferenceAlenius, G. M., Eriksson, C., and Rantapää Dahlqvist, S. ( 2009 ) Interleukinâ 6 and soluble interleukinâ 2 receptor αâ markers of inflammation in patients with psoriatic arthritis? Clin. Exp. Rheumatol. 27, 120 â 123.
dc.identifier.citedreferenceChandran, V., Cook, R. J., Edwin, J., Shen, H., Pellett, F. J., et al. ( 2010 ) Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. Rheumatology (Oxford) 49, 1399 â 1405.
dc.identifier.citedreferenceRamonda, R., Modesti, V., Ortolan, A., Scanu, A., Bassi, N., et al. ( 2013 ) Serological markers in psoriatic arthritis: promising tools. Exp. Biol. Med. (Maywood) 238, 1431 â 1436.
dc.identifier.citedreferenceChandran, V., Shen, H., Pollock, R. A., Pellett, F. J., Carty, A., et al. ( 2013 ) Soluble biomarkers associated with response to treatment with tumor necrosis factor inhibitors in psoriatic arthritis. J. Rheumatol. 40, 866 â 871.
dc.identifier.citedreferenceDalbeth, N., Pool, B., Smith, T., Callon, K. E., Lobo, M., et al. ( 2010 ) Circulating mediators of bone remodeling in psoriatic arthritis: implications for disordered osteoclastogenesis and bone erosion. Arthritis Res. Ther. 12, R164.
dc.identifier.citedreferenceTeitelbaum, S. L., and Ross, F. P. ( 2003 ) Genetic regulation of osteoclast development and function. Nat. Rev. Genet. 4, 638 â 649.
dc.identifier.citedreferenceSuzuki, E., Mellins, E. D., Gershwin, M. E., Nestle, F. O., and Adamopoulos, I. E. ( 2014 ) The ILâ 23/ILâ 17 axis in psoriatic arthritis. Autoimmun. Rev. 13, 496 â 502.
dc.identifier.citedreferenceZenz, R., Eferl, R., Scheinecker, C., Redlich, K., Smolen, J., et al. ( 2008 ) Activator protein 1 (Fos/Jun) functions in inflammatory bone and skin disease. Arthritis Res. Ther. 10, 201.
dc.identifier.citedreferenceKim, N., Kadono, Y., Takami, M., Lee, J., Lee, S. H., et al. ( 2005 ) Osteoclast differentiation independent of the TRANCEâ RANKâ TRAF6 axis. J. Exp. Med. 202, 589 â 595.
dc.identifier.citedreferenceRitchlin, C. T., Haasâ Smith, S. A., Li, P., Hicks, D. G., and Schwarz, E. M. ( 2003 ) Mechanisms of TNFâ αâ and RANKLâ mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J. Clin. Invest. 111, 821 â 831.
dc.identifier.citedreferenceXue, Y., Jiang, L., Cheng, Q., Chen, H., Yu, Y., et al. ( 2012 ) Adipokines in psoriatic arthritis patients: the correlations with osteoclast precursors and bone erosions. PLoS One 7, e46740.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
iub1453.pdf
Size:
223.9KB
Format:
PDF
View/Open
Name:
iub1453_am.pdf
Size:
180.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe its collections in a way that respects the people and communities who create, use, and are represented in them. We encourage you to Contact Us anonymously if you encounter harmful or problematic language in catalog records or finding aids. More information about our policies and practices is available at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.